Hikma Pharmaceuticals Regulatory News (HIK)

Hikma Pharmaceuticals PLC

Interim Dividend for 2012

LONDON, 4 October 2012 - Hikma Pharmaceuticals PLC ("the Company") advises that, as previously announced with the interim results, the interim dividend of 6.0 cents per will be paid on 08 October 2012 to shareholders on the register on 31 August 2012.

Shareholders who have elected to receive their dividend in Pounds Sterling will receive 3.694 pence per Ordinary Share (exchange rate US$1.6241 to GBP£1).

Shareholders who have elected to receive their dividend in Jordanian Dinar will receive 4.248 qirsh (piastres) per Ordinary Share (exchange rate US$0.708 to JOD1).

- ENDS -

Enquiries:

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.